Pilot Study for the SQUEEZE Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Septic Shock
Interventions
OTHER

Fluid Sparing Resuscitation Strategy

"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."

Trial Locations (1)

L8S 4K1

McMaster Children's Hospital, Hamilton

All Listed Sponsors
collaborator

Hamilton Health Sciences Corporation

OTHER

collaborator

McMaster University

OTHER

collaborator

Canadian Critical Care Trials Group

OTHER

lead

McMaster Children's Hospital

OTHER

NCT01973907 - Pilot Study for the SQUEEZE Trial | Biotech Hunter | Biotech Hunter